


INFORMATION DISCLOSURE CITATION (Use Several Sheets if necessary)	Docket Number 13773-7		Application Number 09/541,795		
	Applicant(s) LINK et al.				
	Filing Date March 31, 2000		Group Art Unit 1624		



U.S. PATENT DOCUMENTS

EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
S	A	4,973,599	1	Gilman et al.	514	398	—
S	B	5,028,629	2	Hite et al.	514	575	—
S	C	5,776,951	3	Arrowsmith et al.	514	328	—
S	D	5,883,106	4	Stevens et al.	514	277	—
S	E	5,883,133	5	Schwart et al.	514	619	—
S	F	5,912,266	6	Perez	514	460	—
S	G	6,110,922	7	Link et al.	514	259	—
S	H	6,329,362	8	Archibald et al.	514	186	—
S	I	S/N 09/285,477	9	Staunton et al.			04/02/99
S	J	S/N 09 285,325	10	Fowler et al.			04/02/99
S	K	S/N 09/606,770	11	Link et al.			06/29/00
S	L	S/N 09/606,717	12	Wang et al.			06/29/00
S	M	SN 09/695,040	13	Gunawardana			10/24/00

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	N
S	N DE 2123383	14	12/02/71	Germany	—	—	✓
S	O GB 2 117 760 A	15	10/19/83	United Kingdom	—	—	—
S	P EP 0219756	16	10/06/86	EPO	—	—	—
S	Q EP 835 867	17	04/15/98	EPO	—	—	—
S	R EP 887 340	18	12/30/98	EPO	—	—	—
S	S JP 12072766	19	03/07/00	Japan	—	—	✓
S	T WO98/39303	20	09/11/98	PCT	—	—	—
S	U WO99/20617	21	04/29/99	PCT	—	—	—
S	V WO99/20618	22	04/29/99	PCT	—	—	—
S	W WO99/49856	23	10/07/99	PCT	—	—	—
S	X WO00/15604	24	03/23/00	PCT	A RST only, in English		
S	Y WO00/15645	25	03/23/00	PCT	11	11	11
S	Z WO00/21920	26	04/20/00	PCT	—	—	—
S	AA WO00/48989	27	08/24/00	PCT	—	—	—
S	AB WO01/06984	28	02/01/01	PCT	—	—	—
S	AC WO01/07052	29	02/01/01	PCT	—	—	—

Handwritten signatures: 13/07/02

9/20/02

O I P E
JIC58

Sheet 2 of 3

AD	AUG 01 2002	WO0127102	04/19/01	PCT		
PATENT & TRADEMARK OFFICE						
		OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)				
30	AE	Ali, H., et al., <i>Mechanisms of Inflammation and Leukocyte Activation</i> , Med. Clin. North America (1997) 81:1-28				
31	AF	Bella, J., et al., <i>The Structure of the Two Amino-terminal Domains of Human ICAM-1 Suggests How it Functions as a Rhinovirus Receptor and As An LFA-1 Integrin Ligand</i> , Proc. Natl. Acad. Sci., USA (1998) 95:4140-4145.				
32	AG	Binnerts, M.E., et al., <i>How LFA-1 Binds to Different Ligands</i> , Immunol. Today (1999) 20:240-245.				
33	AH	Boschelli, D.H., et al., <i>Inhibition of E-Selectin-, ICAM-1-, and VCAM-1-Mediated Cell Adhesion by Benzo(b thiophene-, Benzofuran-, Indole-, and Naphthalene-2-Carboxamides: Identification of PD 144795 as an Antiinflammatory Agent</i> , J. Med. Chem. (1995) 38:4597-4614.				
34	AI	Carlos, T.M., <i>Leukocyte-Endothelial Adhesion Molecules</i> , Blood (1994) 84:2068-2101				
35	AJ	Edwards, C.P. et al., <i>Mapping the Intercellular Adhesion Molecule-1 and -2 Binding Site on the Inserted Domain of Leukocyte Function-associated Antigen-1</i> , J. Biol. Chem. (1998) 273:28937-28944.				
36	AK	Emeigh, J.E., et al., <i>Small Molecule Antagonists of LFA-1-Mediated Cell Adhesion</i> , 221st ACS National Meeting, San Diego, CA, USA (2001) MEDI 256				
37	AL	Fisher, K.L., et al., <i>Identification of the Binding Site in Intercellular Adhesion Molecule 1 for its Receptor, Leukocyte Function-associated Antigen 1</i> , Mol. Biol. Cell (1997) 8:501-515.				
38	AM	Gadek, T.R., et al., <i>Identification and Characterization of Antagonists of the LFA-1/ICAM-1 Protein-Protein Interaction as Novel Immunomodulatory Agents</i> , 220th ACS National Meeting, Washington, D.C., USA (2000) MEDI 177				
39	AN	Gahmberg, C.G., <i>Leukocyte Adhesion: CD11/CD18 Integrins and Intercellular Adhesion Molecules</i> , Curr. Opin. Cell Biol. (1997) 9:643-650				
40	AO	Gahmberg, C.G., <i>Leukocyte Adhesion: Structure and Function of Human Leukocyte β_2-integrins and Their Cellular Ligands</i> , Eur. J. Biochem. (1997) 245:215-232.				
41	AP	Green, J.M., <i>T Cell Receptor Stimulation, But Not CD28 Costimulation, Is Dependent on LFA-1-Mediated Events</i> , Eur. J. Immunology (1994) 24:265-272				
42	AO	Hamilton, G.S., et al., <i>Fluorenlylalkanoic and Benzoic Acids as Novel Inhibitors of Cell Adhesion Processes in Leukocytes</i> , J. Med. Chem. (1995) 38:1650-1656.				
43	AR	Henricks, P.A., <i>Pharmacological modulation of cell adhesion molecules</i> , Eur. J. Pharmacol. (1998) 344:1-13				
44	AS	Huang, C., <i>A Binding Interface on the I Domain of Lymphocyte Function-associated Antigen-1 (LFA-1) Required for Specific Interaction with Intercellular Adhesion Molecule 1 (ICAM-1)</i> , J. Biol. Chem. (1995) 270:19008-19016				
45	AT	Huth, J.R., <i>NMR and Mutagenesis Evidence for an I Domain Allosteric Site That Regulates Lymphocyte Function-associated Antigen 1 Ligand Binding</i> , Proc. Natl. Acad. Sci., USA (2000) 97:5231-5236.				
46	AV	Kallen, J., et al., <i>Structural Basis for LFA-1 Inhibition upon Lovastatin Binding to the CD11a I-Domain</i> , J. Mol. Biol. (1999) 292:1-9				
47	AV	Kelly, T.A., <i>Cutting Edge: A Small Molecule Antagonist of LFA-1-Mediated Cell Adhesion</i> , J. Immunol. (1999) 163:5173-5177				
48	AV	Kishimoto, T.K., <i>Integrins, ICAMs and Selectins: Role and Regulation of Adhesion Molecules in Neutrophil Recruitment to Inflammatory Sites</i> , Adv. Pharmacol. (1994) 25:117-169				
49	AV	Landis, R.C., <i>Involvement of The "I" domain of LFA-1 in Selective Binding to Ligands ICAM-1 and ICAM-3</i> , J. Cell Biol. (1994) 126:529-537				
50	AY	Link, J.T., et al., <i>Discovery and SAR of Diarylsulfide Cyclopropylamide LFA-1/ICAM-1 Interaction Antagonists</i> , Bioorg. Med. Chem. Lett. (2001) 11:973-976				
51	Z	Liu, G., <i>Small Molecule Antagonists of the LFA-1/ICAM-1 Interaction as Potential Therapeutic Agents</i> , Expert Opin. Ther. Patents (2001) 11(9):1383-1393.				
52	BA	Liu, G., et al., <i>Discovery of Novel P-arylsulphio Cinnamides as Antagonists of Leukocyte Function-associated Antigen-1/intracellular Adhesion Molecule-1 Interaction, 1. Identification of an Additional Binding Pocket Based on an Anilino Diaryl Sulfide Lead</i> , J. Med. Chem. (2000) 43:4025-4040				
53	BB	Liu, G., et al., <i>Novel P-arylsulphio Cinnamides as Antagonists of Leukocyte Function-associated Antigen-1/intracellular Adhesion Molecule-1 Interaction, 2. Mechanism of Inhibition and Structure-based Improvement of Pharmaceutical Properties</i> , (2001) J. Med. Chem. 44:1202-1210.				

Handwritten: 5/20/02

10002 55	BE TRADEMARK OFFICE	Lu, C., et al., <i>An Isolated, Surface-expressed I Domain of the Integrin Alβ2 Is Sufficient for Strong Adhesive Function When Locked in the Open Conformation with a Disulfide Bond</i> . Proc. Natl. Acad. Sci. USA (2001) 98:2387-2392
10002 55	BE	Nakano, T., et al., <i>Adxanthromycins A and B, New Inhibitors of ICAM-1/LFA-1 Mediated Cell Adhesion Molecule from Streptomyces NA-148</i> . J. Antibiot. (Tokyo) (2000) 53:12-18
10002 55	BE	Pei, Z., et al., <i>Discovery of Potent Antagonists of Leukocyte Function-associated Antigen-1/intercellular Adhesion Molecule-1 Interaction. 3. Amide (C-ring) Structure-activity Relationship and Improvement of Overall Properties of Arylthio Cinnamides</i> . J. Med. Chem. (2001) 44:2913-2920
10002 55	BF	Qu, A., et al., <i>The Role of the Divalent Cation in the Structure of the I Domain from the CD11a/CD18 Integrin</i> , Structure (1996) 4:931-942.
10002 55	BF	Sanfilippo, P.J., <i>Novel Thiazole Based Heterocycles as Inhibitors of LFA-1/ICAM-1 Mediated Cell Adhesion</i> , J. Med. Chem. (1995) 38:1057-1059
10002 55	BH	Springer, T.A., <i>Adhesion Receptors of the Immune System</i> , Nature (1990) 346:425-434
10002 55	BJ	Stanley, P., et al., <i>The I Domain of Integrin LFA-1 interacts with ICAM-1 Domain 1 at Residue Glu-34 But Not Gln-73</i> , J. Biol. Chem. (1998) 273:3358-3362.
10002 55	BJ	Winn, Martin et al., <i>Discovery of Novel p-Arylthio Cinnamides as Antagonists of Leukocyte Function-Associated Antigen-1/Intercellular Adhesion Molecule-1 Interaction. 4. Structure-Activity Relationship of Substituents on the Benzene Ring of the Cinnamide</i> , J. Med. Chem. (2001) 44:4393
10002 55	BK	Zhu, G., et al., <i>Diels-Alder Reactions of Hexafluoro-ω-butyne with 2-Heterosubstituted Furans: A Facile and General Synthesis of 1,4-Disubstituted 2,3-Di(trifluoromethyl) benzenes</i> , Organic Letters (2000) 2(21):3345
EXAMINER	<i>Frederick B. Babb</i>	DATE CONSIDERED 9/20/02

•EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

RECEIVED

09/20/2002

TECHNOLOGY 600/2000



DATE: April 18, 2000 SHEET _1_ of _2

Form PTO-1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

SERIAL NO.

6446.US.P2

09/541,795

APPLICANT

J. Link, et al.

FILING DATE

03/31/00

GROUP

(not yet assigned)

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

(37 CFR 1.98 (b))

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER							ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE
826	5	8	1	7	8	6	2	10/06/98	Poetsch et al.			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER		PUBLIC- ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION					
							YES	NO					
826		9	8	1	3	3	4	7	02.04.98	PCT			
826		9	9	1	1	2	5	8	11.03.99	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

826	Springer, T.A., 1994, Traffic Signals for Lymphocyte Recirculation and Leukocyte Emigration: The Multistep Paradigm, CELL, 76: 301-314.
826	Lawrence, M.B., Springer, T.A., 1991, Leukocytes' Roll on a Selectin in Physiologic Flow Rate: Distinction from and Prerequisite for Adhesion Through Integrins, CELL, 65:859-873.
826	Von Adrian, V., Chambers, J.D., McEnvoy, L.M. Bargatze, R.F., Arfoss, K.E., Butcher, E.C., 1991, Two-Step Model of Leukocyte-Endothelial Cell Interactions in Inflammation, Proc. National Acad. Sci. USA, 88:7538-7542.
826	Ley, K., Gaehtgens, P., Fennie, C., Singer, M.S., Lasky, L.H., Rosen, S.D., 1991, Lectin-Like Cell Adhesion Molecule 1 Mediates Rolling in Mesenteric Venules, <i>in vivo</i> , BLOOD, 77:2553-2555.
826	Higuchi, T., Stella, V., Pro-drugs as Novel Delivery Systems, Vol. 14 of the A.C.S. SYMPOSIUM SERIES.
826	Roche, E.B., Bioreversible Carriers in Drug Design, AMERICAN PHARMACEUTICAL ASSOCIATION AND PERGAMON PRESS, 1987.
826	Prescott, E., Methods in Cell Biology, Volume XIV, Academic Press, New York, NY (1976), p. 33 et seq.
826	Berge, S.M., et al., J. PHARMACEUTICAL SCIENCES, 1977, 66:1 et seq.
826	Kakimoto, et al., CELL IMMUNOL 142:326-337, 1992.
826	Knoerzer, et al., TOXICAL PATHOL 25:13-19, 1997.

826
4/18/2000



DATE: April 18, 1999 SHEET 2 of 2

Form PTO-1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 6446.US.P2	SERIAL NO. 09/541,795
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT J. Link, et al.	
		FILING DATE 03/31/00	GROUP (not yet assigned)
(37 CFR 1.98 (b))			

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

		Halloran, et al., ARTHRITIS RHEUM 39:810-819, 1996.
		Schimmer, et al., J. IMMUNOL 160: 1455-1477, 1998.
		Oppenheimer-Marks, et al., J. CLIN INVEST 101: 1261-1272, 1998.
		Wegner, et al., SCIENCE 247:456-459, 1990.
		Bloemen, et al., AM J. RESPIR CRIT CARE MED 153:521-529, 1996.
		Wegner, et al., LUNG 170: 267-279, 1992.
		Mulligan, et al., J IMMUNOL 154:1350-1363, 1995.
		Nagase, et al., AM J RESPIR CRIT CARE MED 154:504-510, 1996.
		Bennet, et al., J PHARMACOL EXP THER, 280:988-1000, 1997
		Hasagawa, et al., INT IMMUNOL, 6:831-838, 1994.
		Herrold, et al., CELL IMMUNOL, 157:489-500, 1994.
		Tanaka, et al., J. IMMUNOL, 151:5088-5095, 1993.
		Kawasaki, et al., J. IMMUNOL, 150:1074-1083, 1993.
		Panes, et al., GASTROENTEROLOGY, 108:1761-1769, 1995.
		Hallahan, et al., PROC NATL ACAD SCI USA, 94:6432-6437, 1997.
		Tamiya, et al., IMMUNOPHARMACOLOGY, 29(1):53-63, 1995.
		Hartman, et al., CARDIOVASC RES, 30(1): 47-54, 1995.
		DeMeester, et al., TRANSPLANTATION, 62(10): 1477-1485, 1996.
		Horgan, et al., AM J PHYSIOL, 261(5):H1578-H1584, 1991.
		Nakanishai, et al., EXP NEUROL, 121:215-219, 1993.
		Chopp, et al., STROKE, 25(4):869-875, 1994.
		Clark, et al., NEUROSURG, 75(4): 623-627, 1991.
		Gute, et al., MOL CELL BIOCHEM, 179: 169-187, 1998.
		Isobe, et al., SCIENCE, 255: 1125-1127, 1992.
		Talento, et al., TRANSPLANTATION, 55: 418-422, 1993.
		Cosimi, et al., J. IMMUNOL, 144: 4606-4612, 1990.
		Nakao, et al., MUSCLE NERVE, 18:93-102, 1995.
		Gorczyński, Wojcik, J. IMMUNOL, 152:2011-2019, 1994.
		He, et al., OPHTHALMOL VIS SCI, 35: 3218-3225, 1994.
		Zeng, et al., TRANSPLANTATION, 58: 681-689, 1994.
		Harning, et al., TRANSPLANTATION, 52: 842-845, 1991.
		Aoudjit, et al., J. IMMUNOL, 161: 2333-2338, 1998.
		Gross, et al., SCIENCE 281, 703-706, 1998.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)